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Key Messages
n

Evidence suggests the demographic age
structure of sub-Saharan Africa is the leading
factor of the low morbidity and mortality of
COVID-19 compared to other regions of the
world.

n

Widespread social mitigation strategies, such as
lockdowns, have resulted in severe economic and
societal consequences in terms of food security,
adolescent pregnancy, gender-based violence,
and disruptions in treating other diseases.

n

It is imperative to weigh the risks and benefits of
social mitigation strategies for future waves.
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BACKGROUND

C

OVID-19 has impacted the world immensely since
its discovery in the city of Wuhan, China, in
December 2019.1,2 As of June 27, 2021, approximately
181.9 million COVID-19 cases have been confirmed with
more than 3.9 million deaths.3 COVID-19 has dramatically
impacted the Americas, Europe, and Asia. As of June 27,
2021, in the Americas, 73.1 million confirmed COVID-19
cases with 1.9 million deaths have been reported, 47.8 million confirmed cases with more than 1 million deaths in
Europe, and 55.4 million confirmed cases with 784,965
deaths in Asia.4
The impact of COVID-19 in Africa has been substantially lower compared to countries in the Americas, Europe,
and Asia. The World Health Organization (WHO) African
Region reported more than 3.9 million confirmed cases
and 94,217 deaths, as of June 27, 2021.5 Moreover, the
mortality rate of COVID-19 per million in Africa is considerably lower than in all other WHO regions other than the
Western Pacific (Table 1).5–11 Public health preparedness is
a significant aspect in the success of reducing COVID19 transmission. Lessons learned from countries
across Eastern Asia imply the need for communityoriented strategies and rapid response from public
health officials to successfully contain the COVID-19
pandemic.12 Strategies such as early case identification, widespread laboratory testing and screening,
outbreak mitigation (up to and including lockdowns), contact tracing, health education, physical
distancing, and quarantine measures have been demonstrated as essential interventions in curbing the
pandemic.
This article critically examines the hypotheses
that have been attributed to the apparently lower
than expected morbidity and mortality of COVID-19
in SSA to help guide public health decision making
regardin g essential interventions for containing
COVID-19.

433

The Conundrum of Low COVID-19 Mortality Burden in sub-Saharan Africa

Lessons learned
from Eastern Asia
imply the need for
communityoriented
strategies and
rapid response
from public health
officials to
successfully
contain the
COVID-19
pandemic.

POTENTIAL MITIGATING FACTORS
INFLUENCING THE MORBIDITY AND
MORTALITY OF COVID-19 IN SUBSAHARAN AFRICA
It is posited that the low impact of COVID-19 in
SSA is due to 1 or several of 6 main hypotheses
(Figure 1).

Hypothesis 1: Demographics of sub-Saharan
Africa
Global mortality trends of COVID-19 show marked
differences by demographic characteristics including age (increased risk of severe illness in older
individuals), sex (higher among males), socioeconomic status, and race (higher among Blacks).
In the United States, the Centers for Disease
Control and Prevention (CDC) report that 80%
of COVID-19-related deaths occur in individuals aged 65 years and older.13,14 Data from
the United Kingdom has demonstrated that the
strongest risk for death is advanced age, which
dramatically outweighs the risks associated with any
other demographic factor or medical condition.15
Demographic structures for Europe, the Americas,
and Asia demonstrate median age ranges from
32 years to 42.5 years,4,16–19 with 8.9% to 19.1% of
the population older than 65 years.20–23
In contrast, the median age of the SSA population is considerably lower, with a median age of
18 and only 3.0% of the African population older
than 65 years.24,25 Figure 2 compares the population pyramids of Uganda and Canada, which are
similar in overall population size. The median age
of Canada (41.1 years) is remarkedly higher than
that of Uganda (16.7 years).26,27 In Uganda, less
than 0.2% of the population is in the highest-risk
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group of developing more severe illness (aged
80 years and older).28 Conversely, the proportion
of individuals aged 80 years and older in Canada is
higher (4.4%).29 Further, Figure 3 illustrates the
distribution of COVID-related deaths in Canada
as of June 25, 2021.30 A large proportion of deaths
are attributed to older age; approximately 98.0%
of COVID-related deaths occur in individuals
aged 50 years and older, with approximately
64.7% in individuals aged 80 years and older.30
With the rollout of COVID-19 vaccinations and
prioritization of those aged 70 years and older in
North America and other areas, the mean age of
those being admitted to hospital has decreased.31,32 However, it is still highly likely that
those aged 70 years and older remain the highest
risk among the unvaccinated population.
Comparison of the age demographics of Uganda
with other lower-middle-income countries in
regions such as Latin America and the Caribbean
and South Asia demonstrates the uniqueness of
the demographic structure in SSA. The median
age in Brazil is 33.5 years, Peru 31.5 years, and
Mexico 29.2 years, which are all markedly higher
than in SSA. Low-income countries in Latin
America and the Caribbean, such as Nicaragua, El
Salvador, and Haiti also have greater median ages
(24.0–27.6 years) and a larger proportion of the
population age 65 and older (5.2%–8.7%) than in
SSA.33–38 Similar demographics are observed for
countries in South Asia, such as India and
Pakistan; median age ranges from 22.8–28.4 years
with 4.4%–6.6% of the population aged older
than 65 years.39–42
Older age is associated with more degenerative
and metabolic disorders that have also been
shown to heighten the risk of death from COVID19. Therefore, it is posited that the demographic

TABLE. Confirmed COVID-19 Cases and Mortality Rates per WHO Regiona
WHO Regionb

COVID-19 Cases

Africa5

COVID-Related Deaths

Populationc

Mortality Rate per Million

3,942,448

94,217

1,019,922,000

92.4

Americas6

71,959,063

1,891,291

992,155,000

1,906.2

South-east Asia7

34,657,785

485,398

1,947,632,000

249.2

55,821,905

1,181,992

916,315,000

1,289.9

10,916,353

215,799

664,336,000

324.8

3,521,244

54,069

1,889,901,000

28.6

Europe

8

Eastern Mediterranean9
10

Western Pacific

Abbreviations: COVID, coronavirus disease; WHO, World Health Organization.
a
Information up to date as of June 27, 2021.
b
Refer to the Supplement for a comprehensive list of WHO Member States.
c
Population data taken from the 2016 WHO Global Health Observatory data repository.11
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FIGURE 1. Proposed Hypotheses Explaining the Limited Impact of COVID-19 in SSA

Abbreviations: COVID-19, coronavirus disease; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2; SSA, sub-Saharan Africa.

FIGURE 2. Population Pyramids of Uganda and Canada28,29

structure of SSA plays a critical role in the low
morbidity and mortality of COVID-19. It is possible that the burden of severe disease and death
may be low despite suspected and undetected
widespread transmission. In fact, it is possible that
widespread transmission has already occurred
Global Health: Science and Practice 2021 | Volume 9 | Number 3

without precipitating the high death rates seen
elsewhere due to the relatively small proportion
of elderly and lack of large long-term care facilities
for the elderly, which have been the epicenters of
mortality in Canada and elsewhere.43 It is notable
that some areas of SSA, such as South Africa, have
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FIGURE 3. Age Distribution of COVID-19 Cases Deceased in Canada as of June 25, 202130

It is possible that
widespread
transmission has
already occurred
without
precipitating the
high death rates
seen elsewhere
due to the
relatively small
proportion of
elderly and lack of
large long-term
care facilities.

a much higher median age (27.6 years), which
could be a reason for the higher COVID-19 death
rates seen there.44

Hypothesis 2: Lack of Long-Term Care
Facilities
In addition to the demographic pyramid demonstrating very low numbers of elderly, the elderly in
SSA do not tend to live in long-term care facilities.
The CDC defines long-term care facilities as those
whereby elderly who are unable to live independently receive medical and personal care.45 Unfortunately,
long-term care facilities pose a significant risk for infectious and communicable diseases; approximately
1.0–3.0 million infections occur in these facilities per
year.45,46 During the first wave of the epidemic in
Canada, 81.0% of all deaths occurred in long-term
care facilities.47 Transmission to the elderly can be particularly efficient in these settings and lead to a markedly higher infection fatality rate.48
Across SSA, long-term care facilities are almost
nonexistent, with the notable exception of South
Africa, leaving the provision of care to families.49,50
Large young families with high levels of unemployment and low labor costs enable care to be provided
by individual relatives rather than a team of professionals, which limits the number of caregivers that
may transmit infection. In the first wave, approximately 33% of South African long-term care facilities
experienced outbreaks.51 Furthermore, data from
South Africa have demonstrated that COVID-19related deaths are highly correlated with increased
age; approximately 2.2% of all COVID-19-related
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deaths occurred among persons younger than
30 years, despite their consisting of 54.2% of the
population.52,53 This is a further potential explanation for South Africa being an outlier with a higher
death rate than in other African countries.54

Hypothesis 3: Prior Exposure to Coronavirus
Infection
In addition to severe acute respiratory syndrome
coronavirus 2 (SARS-CoV-2), the virus that
causes COVID-19, 6 other human coronaviruses
have been identified. Seasonal human coronaviruses, such as NL6, 229E, OC43, and HKU1, are
common and result in cold- or flu-like symptoms.55 Zoonotic coronaviruses, such as Middle
East Respiratory Syndrome (MERS)-CoV and
SARS-CoV, are responsible for more severe diseases.55 Previous exposure to locally circulating coronaviruses and the development of antibodies is
posited to mediate cross-protection to COVID-19
and induce partial immunity.56
Several studies have been conducted to investigate this unique relationship. Studies assessing
antibody prevalence to SARS-CoV-2 in prepandemic serum samples observed a significant
increase in the prevalence of cross-reactivity
among sera in SSA compared to other continents.57 In addition, previous studies have
demonstrated high false positivity when testing
pre-pandemic sera from SSA using European
assays.58,59 The discrepancy of seropositivity may
be attributed to widespread exposure to various
endemic coronaviruses before the emergence of
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the SARS-CoV-2 pandemic. A limitation of these
studies was the use of serological assays to determine previous exposure, particularly because
there can be discrepancies in results when comparing T-cell versus antibody evidence of exposure and immunity.60 In contrast, a study by
Sagar et al.61 used results from previously performed comprehensive respiratory panel polymerase chain reaction assays to examine the
impact of previous exposure to endemic coronaviruses in COVID-19 patients. Their results demonstrated a significant decrease in odds of
mortality and odds of being admitted to an intensive care unit in patients who had evidence for
previous exposure to endemic coronaviruses compared to those who did not.56,61 These findings indicate that exposure to other coronaviruses may
reduce the severity and burden of COVID-19.
Furthermore, a recent study by Uyoga et al.62 observed increased rates of antibody prevalence to
SARS-CoV-2 among Kenyan blood donors between April 30–June 16, 2020, that are higher
than case counts would predict.

Hypothesis 4: Limited Access to Adequate
Testing
There are concerns regarding the recording of
COVID-19 cases in SSA. It is hypothesized that
there has been a dramatic undercounting of
deaths due to lack of SARS-CoV-2 testing as was
suggested in the mass media to have happened in
Kano, Nigeria.63,64 Current data may not reflect
the true extent of the disease. The true numbers
of infected and deaths could be higher given that,
at least in South Africa where the median age is
much higher than SSA as a whole,44 the excess
mortality observed is far higher than the officially
reported totals for deaths from COVID-19. Lack of
local access to testing and contact tracing, and insufficient data collection have interfered with the
ascertainment of the incidence and prevalence of
COVID-19 in SSA. The WHO reports varying
levels of testing across Africa, however, testing is
still relatively low compared to other areas of the
world.65 As of June 25, 2021, testing rates ranged
from as low as 7.7 tests per 1,000 population in
Madagascar to as high as 215.3 and 389.9 tests
per 1,000 in South Africa and Gabon, respectively.66
However, these numbers are far lower than rates in
the United States (1,401.8 tests per 1,000 population) and the United Kingdom (2,973.0 tests per
1,000 population).66 Although low testing rates likely resulted in a much lower case rate, the lack of hospital overcrowding and widespread deaths likely
Global Health: Science and Practice 2021 | Volume 9 | Number 3
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resulted from lower morbidity and mortality in this
region. This would suggest a lower predisposition to
severe illness. The initial priority for the Africa Task
Force for Novel Coronavirus was to expand COVID19 testing capability. This expansion proceeded rapidly; at the outset of the pandemic, only 2 labs in
Africa were capable of SARS-CoV-2 detection, but
by mid-March 2020, 43 countries had this laboratory capability.67 Preliminary observations from the
poorly maintained civil and vital registration systems seem to indicate that it is unlikely that there
has been excess all-cause mortality in the region.68
Studies are underway in Kenya assessing excess
mortality through verbal autopsies and populationbased serosurveys for past infections to assess past
exposure.69
The concerns of recording the impact of COVID19 across SSA offers the opportunity of novel means
of data collection to expand current knowledge on
COVID-19 morbidity and mortality. Morbidity may
be further explored through the use and purchase of
oxygen as a proxy of the current situation in hospitals. Further, data collection on death may be extended to churches and faith groups, obituaries,
and morticians. These and other means should be
further explored to help better understand the impact of COVID-19 on SSA as a whole.
There is a
hypothesis that
Studies from developed countries have demonstrat- deaths have been
ed a higher risk of death in racialized communities, undercounted due
including those of African or South Asian descent.15 to lack of SARSThis predisposition is likely related to socioeconomic CoV-2 testing.

Hypothesis 5: Genetic Risk Factors

factors including poverty, crowding, and working in
essential services. Therefore, overall environmental
exposures are likely far more important than genetic
exposures in disease susceptibility.

Hypothesis 6: Effective Government Public
Health Response to COVID-19 Threat
Another hypothesis is that African governments
and public health organizations moved remarkably swiftly in response to the threat of COVID19. Early in January 2020, African governments
began to plan for the arrival of COVID-19 as high
flight volumes between China and Africa predicted early spread to multiple locations including
South Africa, Nigeria, and Kenya.70 As early as
January 2, 2020, Côte d’Ivoire implemented enhanced screening measures for passengers arriving from China.71 Other African countries swiftly
followed suit. In February 2020, the first meeting
of the newly established Africa Task Force for
Novel Coronavirus convened. The first confirmed

Another
hypothesis is that
African
governments and
public health
organizations
moved
remarkably swiftly
in response to the
threat of
COVID-19.
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case of COVID-19 on the African continent was
reported in Egypt on February 14, 2020, and
linked to travel from China. By March, almost
all African nations had suspended flights from
China. After March 2020, most cases imported to
Africa originated from Europe, as the epicenter of
the disease had shifted there.72 By May 2020,
more than 40 African nations had closed their borders to all but cargo.71
National public health institutions are responsible for disease surveillance, diagnostics, and rapid response to outbreaks, making them essential
for curbing the emergence and re-emergence
of infectious diseases in the African context,
especially COVID-19.73 As of 2019, Botswana,
Ethiopia, Ghana, Liberia, Morocco, Mozambique,
Namibia, Nigeria, Rwanda, Sierra Leone, South
Africa, Uganda, and Zambia all had highly functional national public health institutions with experience in battling infectious diseases.73,74 These
organizations focus on infectious disease threats,
which is in contrast to those organizations in
high-income countries that have focused on noncommunicable diseases. Uganda is a leading example of curbing the impact of COVID-19 in the
African context. Rapid response and implementation of risk communication, testing, social and
physical distancing measures, and contract tracing
were critical for the success seen in Uganda.75
Additionally, new programs to promote regional sharing of COVID-related information
were initiated across SSA. For example, the East
African Community created the Regional
Electronic Cargo and Drivers Tracking System.
This system electronically shares the COVID test
results of truck drivers between member countries.
In addition, the program uses the drivers’ cell phones
to track their routes and record stops. This tracking
allows for quick contact tracing in the event of a
COVID-19 outbreak.76 Furthermore, several African
countries have scored particularly well in critical policy areas in terms of public health directives, financial
responses, and fact-based public communications to
help control COVID-19.77 In particular, Kenya,
Ghana, and Ethiopia scored more than 95 on a
100-point scale.77 This may have helped to mitigate
the scope of the pandemic although further validation of the scores would be helpful.

Other Hypotheses
Adherence to Preventative Strategies
Some studies suggest that adherence to recommendations for handwashing, social distancing, and public masking has been widespread in SSA,78,79
Global Health: Science and Practice 2021 | Volume 9 | Number 3
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however, the generalizability of these observations
to multiple SSA countries and contexts, as well as
comparative data between African and non-African
countries require further study.

Drugs Against Parasitic Infections
Infections with parasites have been suggested to
be associated with less severe COVID-19 in an as
yet non-peer-reviewed Ethiopian study although
this finding requires replication in other locales.80
SSA countries within the tropical and equatorial
regions appear to have the lowest proportion of
confirmed COVID-19 cases and the highest burden of malaria infection.81 Several factors have
been posited to contribute to the low incidence of
COVID-19 in these malaria-endemic countries,
including cross-protection from consistent use of
antimalarial medication.81 However, the failure
of hydroxychloroquine to prevent COVID-19 in
randomized studies makes this hypothesis less
likely.82 In addition, ivermectin, an antiparasitic
drug used to treat several neglected tropical diseases, such as onchocerciasis, strongyloidiasis,
and lymphatic filaria,83,84 has been widely used
across SSA since the 1990s.85 A study conducted
by Caly et al.86 found ivermectin to be an inhibitor
of the SARS-CoV-2 virus in vitro. Despite the hypothesized association between antiparasitic medications and COVID-19, at present, there is still
only limited evidence to support it.87,88

Prevalence of Noncommunicable Diseases
Noncommunicable diseases, such as hypertension, diabetes, and obesity, have been observed to
increase the severity of COVID-19 illness.89 In
comparison to North America, the rates of noncommunicable diseases, such as diabetes and obesity, are remarkedly lower in SSA. Data from 2017
demonstrate that the prevalence of diabetes in the
United States and Canada was observed to be
10.8% and 7.4%, respectively.90 Conversely, the
prevalence of diabetes among SSA was observed
to range from 1.0%–7.8%, with exception of
Sudan and South Sudan, whereby the prevalence
of diabetes was 15.7% and 10.4%, respectively.90
Further, approximately 70.2% and 67.5% of
adults in the United States and Canada, respectively, have been observed to be either overweight
or obese (BMI greater than 25).91 Conversely,
among countries in SSA, these rates range from
18.1%–38.4%, with exception of South Africa
whereby 51.9% of adults are either overweight
or obese.91 The prevalence of hypertension, however, is considerably higher in SSA compared to
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North America.92 Further studies should be conducted to understand the roles of noncommunicable diseases and COVID-19 severity in the
African context.

Mobility
It also has been hypothesized that lower mobility and spending a greater amount of time outdoors may have reduced the risk of COVID-19,
especially in impoverished rural areas. 93
Reduced travel between African countries due
to limited visa-free relationships may have also
limited spread across the continent. 94 Further
study would be necessary to confirm these
hypotheses.

IMPLICATIONS FOR POLICIES AND
PROGRAMS
Based on the current COVID-19 situation in SSA, to
help policy makers and programs improve health
practice, the following policy prescriptions have
emerged:


Reduce emphasis on lockdowns, which may
disproportionately affect young people and the
poor and may lead to other severe health consequences as noted in the article.



Emphasize the importance of good governance regarding health directives and open communication.



Provide financial support to vulnerable sectors
as per experience in Kenya and Ghana.77 In
light of the limited resources of many African
countries, this may require the assistance of external agencies.



Prioritize an international effort to develop vaccines tailored to the SARS-CoV-2, 501.V2.



The impact of oxygen shortages in a developing
country suffering a COVID-19 outbreak has been
severely apparent in India.102,103 Therefore, governments must ensure the availability of medical
infrastructure should an unexpected rapid
system-wide severe outbreak occur.



Prioritize efforts to establish molecular epidemiology to be aware of the emergence of new
variants. In particular, the emergence of new
variants of concern, which may be more virulent in younger populations, would require a Diabetes and
reconsideration of Africa’s susceptibility to a se- obesity have been
observed to
vere epidemic.



Conduct studies to determine the risk factors
for severe disease in the African context. These
may include detailed cohort studies of patients
who do get severely ill in SSA countries with
appropriate controls (such as patients who test
negative for SARS-CoV-2).

SOUTH AFRICA AS AN OUTLIER
South Africa appears to have had a particularly
high incidence of COVID-19 hospitalizations and
deaths. This has been attributed to several phenomena. As noted above, South Africa has a
higher median age as well as an established longterm care facility sector. The very high HIV and
TB burden in South Africa may be another factor
as both of these were found to be associated with
an increased COVID-19 mortality rate in a South
African cohort.54 Maintaining antiretroviral therapy is particularly important in light of the data
demonstrating poor COVID-19 outcomes in
patients with low CD4 counts.95 In addition, the
effects of noncommunicable diseases may contribute to the higher burden of COVID-19 seen in
South Africa. The prevalence of hypertension in
South Africa has been reported to range from
26.9%–30.4% and is increasing.96,97 Furthermore,
the prevalence of diabetes in South Africa has been
reported to be 12.8%98 and was found to be the
second leading cause of death in South Africa
in 2015. 99 Moreover, obesity rates among men
and women in South Africa have been reported
to be 31.0% and 68.0%, respectively. Further
research needs to be conducted on various noncommunicable factors that may contribute to
the increased COVID-19 burden seen in South
Africa.
Better diagnostics and health care documentation, including death registries, may also allow for
higher reporting rates. The emergence of the
SARS-CoV-2 variant, 501.V2, has demonstrated
the potential for greater transmissibility and risk
of reinfection as well as a concern of relative vaccine resistance, leading to severe future waves of
infection in South Africa.100,101
Global Health: Science and Practice 2021 | Volume 9 | Number 3
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CONCLUSIONS

increase the
severity of COVID19 illness, but the
rates of diabetes
and obesity are
remarkedly lower
in SSA compared
to North America.

In reviewing the totality of the evidence, we believe that it is suggested that in SSA the overall
death rate is lower than in most other regions primarily due to the demographic structure with a
low median age and a small percentage of vulnerable elderly, although as noted, other factors likely
also play a role. Some localized areas with a greater number of older individuals, such as South
Africa, may be exceptions to this trend. The presence of a long-term care facility sector as well as
extremely high rates of HIV and TB coinfection,

439

The Conundrum of Low COVID-19 Mortality Burden in sub-Saharan Africa

and effects of noncommunicable diseases may also
have led to South Africa having a higher disease
burden. Limited resources for disease diagnosis,
effective public health campaigns, and other factors discussed are also important considerations.
Further studies to clarify these various hypotheses
for the low mortality presently reported in Africa
are required. While data accrue, the risks and benefits of widespread social mitigation strategies
such as lockdowns, need careful consideration.
The continent is reeling from the effects of the
pandemic; the economic and societal tolls in terms
of hunger, teen pregnancy, gender-based violence, and disruptions in the treatment of malaria,
TB, and HIV are enormous. Furthermore, the 501.
V2 variant of SARS-CoV-2 heightens the risks of
further waves and raises the risk to the rest of the
continent, including the danger of hospitals reaching capacity in other SSA countries.104 However,
as discussed, widespread adoption of stringent
lockdown strategies used previously should be undertaken only with great caution. Consideration
must be given to local, unique conditions such as
the age structure of the population, competing
health risks, and food security.104
With the recent experience of a severe second
wave in India, it is imperative to establish adequate molecular epidemiology to monitor emerging variants that have the potential to cause severe
infection in the younger population. As full vaccine rollout in Africa with widespread coverage
will likely not occur for some time, these issues remain of critical importance. This review of the literature will aid countries in adopting unique
strategies for limiting the spread of COVID-19 without the need for stringent lockdowns. Further research on the potential mechanisms needs to be
carried out to understand other possible reasons for
the observed discrepancy in mortality seen in SSA.
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